CureVac (NASDAQ:CVAC) Trading 9.9% Higher

Shares of CureVac (NASDAQ:CVAC) traded up 9.9% on Monday . The company traded as high as $3.01 and last traded at $3.01. 307,717 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 953,040 shares. The stock had previously closed at $2.74.

Analysts Set New Price Targets

Separately, JMP Securities decreased their target price on CureVac from $18.00 to $16.00 and set a “market outperform” rating for the company in a report on Friday, August 16th.

CureVac Stock Down 0.7 %

The company’s fifty day simple moving average is $3.32 and its 200 day simple moving average is $3.29. The company has a quick ratio of 2.28, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $678.36 million, a PE ratio of -2.29, a price-to-earnings-growth ratio of 1.94 and a beta of 2.62.

CureVac (NASDAQ:CVAC) last released its earnings results on Thursday, August 15th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). The firm had revenue of $15.55 million during the quarter, compared to analysts’ expectations of $10.07 million. CureVac had a negative net margin of 422.66% and a negative return on equity of 57.18%. Analysts anticipate that CureVac will post 0.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Vanguard Personalized Indexing Management LLC bought a new stake in CureVac in the fourth quarter worth $68,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in CureVac by 45.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 44,122 shares of the company’s stock worth $184,000 after buying an additional 13,687 shares during the last quarter. Signaturefd LLC lifted its stake in shares of CureVac by 232.0% in the second quarter. Signaturefd LLC now owns 22,043 shares of the company’s stock worth $75,000 after buying an additional 15,403 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of CureVac during the fourth quarter valued at approximately $160,000. Finally, Aristides Capital LLC bought a new stake in shares of CureVac during the fourth quarter valued at approximately $100,000. 17.26% of the stock is currently owned by institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.